Brain Cancer Clinical Trial
— 5C-pilotOfficial title:
Controlling Coordination After Childhood Cerebellar Cancer - Pilot Study
NCT number | NCT04501731 |
Other study ID # | 20047 |
Secondary ID | |
Status | Recruiting |
Phase | |
First received | |
Last updated | |
Start date | April 28, 2022 |
Est. completion date | December 31, 2022 |
Posterior fossa tumours (PFT) account for 2/3 of childhood brain cancers. They can be highly malignant requiring combined chemotherapy and radiotherapy post-surgery for a >50% chance of cure. PFT frequently involve the cerebellum which is responsible for coordinating movement, balance, emotional control, and links closely to control of affect and executive function. PFT survivors show highly variable profiles for cognitive and sensorimotor functioning which are influenced strongly by the severity of the pre-diagnostic or post-surgical brain injury State-of-the-art magnetic resonance imaging (MRI) scans can allow to measure a variety of different biological processes in the brain, and the investigators believe that some of these MRI measures (called MRI biomarkers) have the potential to improve our ability to understand and monitor consequences of the ablative brain surgery and complex mechanisms of motor skills recovery. Biomarkers are very important for the development of intervention because 1) they help understand the recuperation process and 2) they allow to effectively assess whether or not a treatment or intervention works. Transcranial magnetic stimulation (TMS) is a powerful non-invasive neuro-modulatory intervention that has the potential to evaluate the integrity of the nervous tracts from the brain to the hand. It is a procedure that applies magnetic pulses on the surface of the scalp to reach underlying brain tissue. TMS has built a reputable status among neuro-rehabilitative research, and there is currently a major effort to translate the positive research findings into clinically useful therapeutic strategies. This study is therefore an important first step towards understanding how potential MRI biomarkers and responses to TMS relate to motor symptoms in PFT young survivors. Once completed, this study will allow the investigators to select the most promising MRI biomarkers and TMS protocols to take forward into future treatment trials. The investigators aim to stimulate the recovery of coordination skills, help the development of targeted therapies, and consequently improve long-term quality of life in children and young people with history of brain tumour. The proposed research intends to prove the feasibility of such brain stimulation and imaging and collect some preliminary measures
Status | Recruiting |
Enrollment | 10 |
Est. completion date | December 31, 2022 |
Est. primary completion date | July 30, 2022 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 16 Years to 22 Years |
Eligibility | Inclusion Criteria: - Able to undergo MRI scan without sedation or general anaesthetic - Able to give informed consent. Exclusion Criteria: - History of seizure - Current cancer or post surgery treatment - Contraindication to TMS or MRI - Pregnancy |
Country | Name | City | State |
---|---|---|---|
United Kingdom | Queen's Medical Centre | Nottingham |
Lead Sponsor | Collaborator |
---|---|
University of Nottingham | Nottingham Hospitals Charity, Nottingham University Hospital NHS Trust |
United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | 5C-pilot Satisfaction Questionnaire | Participants rating their experience of MRI, TMS and motor assessment | 6 months | |
Primary | Completion rate of the sessions of TMS, MRI and motor tasks | Measure of quality of MRI images (participants motion) - Feasibility will be confirmed if 50% or more of these participants complete the TMS session | 6 months | |
Secondary | Anatomical MRI metrics (PFT vs control) | Cerebellar volumetry and cerebellar parcellation - after surgery (mm3) | 1 year | |
Secondary | fMRI metrics (PFT vs control) | Functional connectivity within sensorimotor network (activation map) | 1 year | |
Secondary | Diffusion MRI metrics (PFT vs control) | Anatomical connectivity within sensorimotor network (tractography) | 1 year | |
Secondary | Single-pulse TMS metrics (PFT vs control) | Resting motor threshold (Stimulus intensity expressed as a percentage of maximal stimulator output) | 1 year | |
Secondary | Single-pulse TMS metrics (PFT vs control) | input-output curve | 1 year | |
Secondary | Single-pulse TMS metrics (PFT vs control) | Silent period (ms) | 1 year | |
Secondary | Single-pulse TMS metrics (PFT vs control) | Short-afferent inhibition | 1 year | |
Secondary | Dual-pulse TMS metrics (PFT vs control) | Intracortical & long-latency inhibition and facilitation | 1 year | |
Secondary | Dual-pulse TMS metrics (PFT vs control) | cerebellar-motor inhibition | 1 year | |
Secondary | Motor performance (PFT vs control) - Reaching and grasping task | Kinematic parameters of movement | 1 year | |
Secondary | Motor performance (PFT vs control) - Grooved pegboard | Score | 1 year | |
Secondary | Motor performance (PFT vs control) - Grip force | Maximum force (N) | 1 year | |
Secondary | Quality of life of PFT survivors: FACT-Peds-Br Questionnaire | FACT-Peds-Br Pediatric Questionnaire - For patients with Brain cancer | 6 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05023434 -
A Study to Measure the Effect of Brain Stimulation on Hand Strength and Function in Patients With Brain Tumors
|
||
Terminated |
NCT01902771 -
Dendritic Cell Vaccine Therapy With In Situ Maturation in Pediatric Brain Tumors
|
Phase 1 | |
Completed |
NCT04114786 -
3D Printed Mask for GBM and Brain Mets
|
N/A | |
Recruiting |
NCT04367779 -
Research of Biomarkers of Response to Proton Beam Therapy in Pediatric and Adult Patients.
|
||
Recruiting |
NCT06058988 -
Trastuzumab Deruxtecan (T-DXd) for People With Brain Cancer
|
Phase 2 | |
Completed |
NCT02911155 -
Cancer and Other Disease Risks in U.S. Nuclear Medicine Technologists
|
||
Completed |
NCT02852655 -
A Pilot Surgical Trial To Evaluate Early Immunologic Pharmacodynamic Parameters For The PD-1 Checkpoint Inhibitor, Pembrolizumab (MK-3475), In Patients With Surgically Accessible Recurrent/Progressive Glioblastoma
|
Phase 1 | |
Completed |
NCT01650922 -
Molecular Genetic Studies of Childhood Brain Tumors and Blood Samples
|
N/A | |
Completed |
NCT00329589 -
A Trial Using Velcade Plus Chemoradiation for Central Nervous System, Head and Neck, and Cervical Cancer Patients
|
Phase 1 | |
Completed |
NCT00505141 -
Urban Environmental Exposures and Childhood Cancer
|
N/A | |
Completed |
NCT00504660 -
6-TG, Capecitabine and Celecoxib Plus TMZ or CCNU for Anaplastic Glioma Patients
|
Phase 2 | |
Completed |
NCT00979810 -
Image-Guided Stereotactic Biopsy of High Grade Gliomas
|
N/A | |
Recruiting |
NCT04899908 -
Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases
|
Phase 2 | |
Active, not recruiting |
NCT02851706 -
Natural History of and Specimen Banking for People With Tumors of the Central Nervous System
|
||
Completed |
NCT02798406 -
Combination Adenovirus + Pembrolizumab to Trigger Immune Virus Effects
|
Phase 2 | |
Completed |
NCT01012609 -
External Beam Radiation Therapy and Cetuximab Followed by Irinotecan and Cetuximab for Children and Young Adults With Newly Diagnosed Diffuse Pontine Tumors and High-Grade Astrocytomas
|
Phase 2 | |
Completed |
NCT00782756 -
Bevacizumab, Temozolomide and Hypofractionated Radiotherapy for Patients With Newly Diagnosed Malignant Glioma
|
Phase 2 | |
Terminated |
NCT03149575 -
VAL-083 Phase 3 Study in Temozolomide-Avastin (Bevacizumab) Recurrent GBM
|
Phase 3 | |
Completed |
NCT01974804 -
Assessment of Early Treatment Response by Diffusion and Perfusion MRI in Patients With Brain Metastasis
|
||
Withdrawn |
NCT01320787 -
18-F-Fluoroacetate as PET Imaging Agent
|
Phase 1 |